Ethics of cancer clinical trials in low-resource settings

Journal of Clinical Oncology

Volumn 32, Issue 28, 2014, Pages 3192-3196

  Joffe, Steven ^a   Miller, Franklin G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); HEALTH CARE POLICY; HEALTH CARE QUALITY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL ETHICS; NEOPLASM; VIRUS TRANSMISSION; COST BENEFIT ANALYSIS; ECONOMICS; ETHICS; HEALTH CARE PLANNING; MEDICAL RESEARCH; NEOPLASMS; STANDARDS;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; ETHICS, MEDICAL; HEALTH RESOURCES; HUMANS; NEOPLASMS;

EID: 84907573758     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.9780     Document Type: Article

References (27)

1. Connor EM, Sperling RS, Gelber R, et al: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331:1173-1180, 1994
2. Lurie P, Wolfe SM: Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med 337:853-856, 1997
3. Angell M: The ethics of clinical research in the Third World. N Engl J Med 337:847-849, 1997
4. Varmus H, Satcher D: Ethical complexities of conducting research in developing countries. N Engl J Med 337:1003-1005, 1997
5. Mbidde E: Bioethics and local circumstances. Science 279:155, 1998
6. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
7. Love RR, Duc NB, Allred DC, et al: Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 20:2559-2566, 2002
8. Love RR, Fost NC: Ethical and regulatory challenges in a randomized control trial of adjuvant treatment for breast cancer in Vietnam. J Investig Med 45:423-431, 1997
9. Guan Z, Xu B, DeSilvio ML, et al: Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol 31:1947-1953, 2013
10. Ades F: Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: Ethical lessons not learned from Africa. J Clin Oncol 31: 4271, 2013
11. Shastri SS, Mittra I, Mishra GA, et al: Effect of VIA screening by primary health workers: Randomized controlled study in Mumbai, India. J Natl Cancer Inst 106:dju009, 2014
12. Sankaranarayanan R, Nene BM, Shastri SS, et al: HPV screening for cervical cancer in rural India. N Engl J Med 360:1385-1394, 2009
13. Nagarajan R: Row over clinical trial as 254 Indian women die. Times of India, April 21, 2014
14. Emanuel EJ, Wendler D, Grady C: What makes clinical research ethical? JAMA 283:2701-2711, 2000
15. Macklin R: Double Standards in Medical Research in Developing Countries. Cambridge, United Kingdom, Cambridge University Press, 2004
16. World Medical Association: World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310:2191-2194, 2013
17. Council for International Organizations of Medical Sciences (CIOMS): International Ethical Guidelines for Biomedical Research Involving Human Subjects. http://www.cioms.ch/publications/guidelines/guidelines-nov-2002-blurb.htm
18. Temple R, Ellenberg SS: Placebo-controlled trials and active-control trials in the evaluation of new treatments: Part 1. Ethical and scientific issues. Ann Intern Med 133:455-463, 2000
19. Joffe S, Miller FG: Equipoise: Asking the right questions for clinical trial design. Nat Rev Clin Oncol 9:230-235, 2012
20. Wertheimer A: Rethinking the Ethics of Clinical Research: Widening the Lens. New York, NY, Oxford University Press, 2011
21. Rid A, Wendler D: A framework for riskbenefit evaluations in biomedical research. Kennedy Inst Ethics J 21:141-179, 2011
22. Wolitz R, Emanuel E, Shah S: Rethinking the responsiveness requirement for international research. Lancet 374:847-849, 2009
23. Participants in the 2001 Conference on Ethical Aspects of Research in Developing Countries: Ethics-Fair benefits for research in developing countries. Science 298:2133-2134, 2002
24. Wertheimer A: Exploitation. Princeton, NJ, Princeton University Press, 1996
25. National Institutes of Health: About NIH: Mission. http://www.nih.gov/about/mission.htm
26. Bill and Melinda Gates Foundation: Who We Are. http://www.gatesfoundation.org/Who-We-Are/General-Information/Foundation-Factsheet
27. Resnik DB: Developing drugs for the developing world: An economic, legal, moral, and political dilemma. Dev World Bioeth 1:11-32, 2001